Hematology/oncology and stem cell therapy最新文献

{"title":"Outcomes and Long-Term Survival of Adolescent and Young Adult Patients Admitted to the Intensive Care Unit Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience of 152 Patients.","authors":"Othman M Solaiman, Tusneem Elhassan, Riad E Fakih, Abdul Mannan, Zainab Alduhailib, Ashwaq A Mahdali, Hazzaa Alzahrani, Mouhamad Jamil, Naeem Chaudhri, Alyaa Elhazmi, Mohammad Kolko, Fahad Z Al-Sharif, Abdullah Alrbiaan, Mohammed Shaban, Marwan Shaheen, Nawal Salahuddin, Feras A Alfraih, Ashraf S Altarifi, Mona Hassanein, Sulaiman Hosaini, Noura Alhashim, Alaa A Mohamed, Amr Hanbali, Ali H Aljanoubi, Nadia R Al-Obaidi, Walid Rasheed, Khalid Maghrabi, Fahad Almohareb, Ayman Soubani, Mahmoud Aljurf, Syed O Ahmed","doi":"10.56875/2589-0646.1114","DOIUrl":"10.56875/2589-0646.1114","url":null,"abstract":"<p><strong>Background and objectives: </strong>Prognostic factors reliably predicting outcomes for critically ill adolescent and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (allo-HSCT) are lacking. We assessed transplant and intensive care unit (ICU)-related factors impacting patient outcomes.</p><p><strong>Patients and methods: </strong>AYA patients who underwent allo-HSCT and required ICU admission at a Tertiary care Centre, during the period of 2003-2013, were included in this retrospective review. This was a non-interventional study. Only outcomes after the first allo-HSCT and index ICU admissions were analyzed. Disease-, transplant-, and ICU-related variables were analyzed to identify risk factors predictive of survival.</p><p><strong>Results: </strong>Overall, 152 patients were included (males, 60.5%); median age at transplantation was 24 years (interquartile range [IQR] 18-32.5); median age at admission to the ICU was 25.8 years (IQR 19-34). Eighty-four percent underwent transplantation for a hematological malignancy; 129 (85%) received myeloablative conditioning. Seventy-one percent of ICU admissions occurred within the first year after allo-HSCT. ICU admission was primarily due to respiratory failure (47.3%) and sepsis (43.4%). One hundred and three patients (68%) died within 28 days of ICU admission. The 1- and 5-year overall survival rates were 19% and 17%, respectively. Main causes for ICU-related death were refractory septic shock with multiorgan failure (n = 49, 32%) and acute respiratory distress syndrome (ARDS) (n = 39, 26%). Univariate analysis showed that ICU mortality was associated with an Acute Physiology and Chronic Health Evaluation (APACHE) II score >20, a sequential organ failure assessment (SOFA score) > 12, a high lactate level, anemia, thrombocytopenia, leukopenia, hyperbilirubinemia, a high international normalized ratio (INR) and acute graft-versus-host disease (GVHD). Multivariate analysis identified thrombocytopenia, high INR, and acute GVHD as independent predictors of mortality.</p><p><strong>Conclusions: </strong>In AYA allo-HSCT patients admitted to the ICU, mortality remains high. Higher SOFA and APACHE scores, the need for organ support, thrombocytopenia, coagulopathy, and acute GVHD predict poor outcomes.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 2","pages":"110-119"},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140338486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report.","authors":"Shahrukh Hashmi, Marwan Shaheen, Salman Adil, Parvez Ahmed, Syed Ahmed, Nour Ben Abdeljelil, Amal Alabdulwahab, Amal Albeihany, Saad Aldaama, Murtadha Al-Khabori, Salam Alkindi, Fahad Almohareb, Ahmed Alsaeed, Amal Alseraihy, Salem Alshemari, Mouhab Ayas, Naeem Chaudhri, Waleed Da'na, David Dennison, Asma ElQuessar, Alaa Elhaddad, Ahmad Ibrahim, Hasan Hashem, Wasil Jastaniah, Hani Mawardi, Amr Nassar, Tariq Satti, Lamia Torjemane, Khalid Tabbara, Hassan El Solh, Bassim Albeirouti, Mahmoud Aljurf","doi":"10.1016/j.hemonc.2020.04.003","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.04.003","url":null,"abstract":"","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"16 4","pages":"303-306"},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.","authors":"Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra","doi":"10.1016/j.hemonc.2020.07.001","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.07.001","url":null,"abstract":"<p><p>Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"16 4","pages":"426-431"},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}